Evidence map›Paper›PMID 41994815›Full record

ArticleCureus2026

Unusual Presentation of Pustular Psoriasis on the Face: A Case Report.

Natalia C Guerra, Trevor Nessel, Ali Moiin

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Natalia C GuerraInternal Medicine, HCA Lawnwood Hospital, Fort Pierce, USA.
Trevor NesselDermatology, Beaumont Hospital, Farmington Hills, USA.
Ali MoiinDermatology, Wayne State University School of Medicine, Detroit, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This case report describes an unusual presentation of pustular psoriasis on the face in a 36-year-old woman with a history of systemic lupus erythematosus (SLE). The patient presented with a rapidly worsening facial rash initially diagnosed as pustular psoriasis with superimposed bacterial impetiginization. Following ineffective initial treatment, she was started on spesolimab, a newly Food and Drug Administration (FDA)-approved monoclonal antibody targeting IL-36R, which led to rapid clinical improvement. The report highlights the clinical challenges of diagnosing pustular psoriasis, particularly in atypical cases, and underscores the importance of early intervention with targeted therapies to prevent disease progression.

Indexed as

acute generalized pustular psoriasisbiologic therapiesgeneralized pustular psoriasis (gpp)management of pustular psoriasispalmoplantar pustular psoriasisspesolimab

Identifiers

PMID41994815
PMCPMC13082300

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.